Partial pancreatic tail preserving subtotal pancreatectomy for pancreatic cancer: Improving glycemic control and quality of life without compromising oncological outcomes

Table 2 Demographic and baseline characteristics

Parameter	PPTP-SP (n = 18)	TP (n = 38)	P value
Male, n (%)	10 (55.6)	22 (57.9)	0.869
Age (yr), mean ± SD	63.9 ± 7.8	62.5 ± 8.9	0.565
BMI (kg/m2), mean ± SD	23.7 ± 3.2	22.3 ± 3.5	0.350
Symptomatic, n (%); Incident, n (%)	12 (66.7); 6 (33.3)	29 (76.3); 9 (23.7)	0.446
Comorbidities, n (%)
Hypertension	4 (22.2)	12 (31.6)	0.469
Preoperative DM	3 (16.7)	11 (28.9)	0.322
Heart diseases	3 (16.7)	4 (10.5)	0.525
COPD	1 (5.6)	1 (2.6)	0.582
Tumor location, n (%)			0.173
Pancreatic head	6 (33.3)	9 (23.7)
Pancreatic body and tail	0 (0.0)	4 (10.5)
Whole pancreas	12 (67.7)	25 (69.4)
Tobacco use, n (%)	6 (33.3)	11 (28.9)	0.739
Alcohol use, n (%)	7 (38.9)	17 (44.7)	0.680
CA19-9 ≥ 37 U/mL, n (%)	15 (83.3)	31 (81.6)	0.872
CA125 ≥ 35 U/mL, n (%)	4 (22.2)	9 (23.6)	0.904
CEA ≥ 10 μg/L, n (%)	2 (11.1)	7 (18.4)	0.475
Preoperative biliary drainage, n (%)	3 (16.7)	8 (21.1)	0.700
Neoadjuvant therapy, n (%)	5 (27.8)	9 (23.7)	0.741
ASA score (II-III), n (%)	10 (55.6)	26 (68.4)	0.348
Preoperative ALB (g/L), median (IQR)	42.0 (39.5-45.5)	40.5 (39.0-43.5)	0.201
Preoperative fasting C-peptide (μg/L), mean ± SD	1.39 ± 0.55	1.14 ± 0.97	0.265
Preoperative fasting insulin (mU/L), mean ± SD	8.80 ± 3.75	7.13 ± 3.58	0.422
Preoperative fasting blood sugar (mg/dL), median (IQR)	5.9 (4.9-6.7)	6.3 (4.2-7.1)	0.207

In the partial pancreatic tail preserving-subtotal pancreatectomy (PPTP-SP) group, ‘location in whole pancreas’ means that the tumor is locating in both the pancreatic head and proximal body. PPTP-SP: Partial pancreatic tail preserving-subtotal pancreatectomy; TP: Total pancreatectomy; BMI: Body mass index; DM: Diabetes mellitus; COPD: Chronic obstructive pulmonary disease; ASA: American Society of Anesthesiologists; ALB: Albumin; SD: Standard deviation; IQR: Interquartile range.